Therapeutic Dupilumab antibody from the original Dupixent® commercial drug

Showing the single result

Filter our product list:
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Expiry Date
Filters Sort results
Reset Apply


Molecular Class
Drug Brand
Product Concentration
Quantity per vial
Storage Temperature
Expiry Date
Monoclonal Antibody
150 mg/mL
12 mg
view product
Max: 10
Min: 0
Step: 1

Not looking for Dupilumab?

Search our therapeutic molecules product database

Dupixent ® - Dupilumab Reference Product

Drug nameDupixent®
API typeDupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Pharmacotherapeutic groupOther dermatological preparations, agents for dermatitis, excluding corticosteroids
ATC codeD11AH05
Target of antibodyIL-13, IL-4
General functionDupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Dupilumab is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO).
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4Rα/IL-13Rα). IL-4 and IL-13 are major drivers of human type 2 inflammatory disease, such as atopic dermatitis, asthma, and CRSwNP. Blocking the IL-4/IL-13 pathway with dupilumab in patients decreases many of the mediators of type 2 inflammation.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)In atopic dermatitis clinical trials, treatment with dupilumab was associated with decreases from baseline in concentrations of type 2 immunity biomarkers, such as thymus and activation-regulated chemokine (TARC/CCL17), total serum IgE and allergen-specific IgE in serum. A reduction of lactate dehydrogenase (LDH), a biomarker associated with AD disease activity and severity, was observed with dupilumab treatment in adults and adolescents with atopic dermatitis. In asthma clinical trials, dupilumab treatment markedly decreased FeNO and circulating concentrations of eotaxin-3, total IgE, allergen specific IgE, TARC, and periostin in asthma subjects.
Original license holder
Marketing authorisation numbersEU/1/17/1229/002
Marketing authorisation holderSanofi-Aventis groupe 54, rue La Boétie 75008 Paris France
Name of the manufacturer of the biological active substanceREGENERON PHARMACEUTICALS INC. 81 Columbia Turnpike RENSSELAER NEW YORK 12144 UNITED STATES; Regeneron Ireland Designated Activity Company (DAC) Ballycummin Raheen Business Park Limerick Ireland; Genzyme Flanders BVBA Cipalstraat 8, B-2440 Geel Belgium
Name and address of the manufacturer(s) responsible for batch releaseSANOFI WINTHROP INDUSTRIE 1051 Boulevard Industriel, 76580 LE TRAIT, FRANCE; Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 Industriepark Hoechst 65926 FRANKFURT AM MAIN GERMANY
Max shelf life3 years
Storage conditions2°C - 8°C
List of excipientsarginine hydrochloride - histidine - polysorbate 80 (E433) - sodium acetate trihydrate - glacial acetic acid (E260) - sucrose - water for injections
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.

we are recruiting